Clinical trial
A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia.
NCT00615433 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia.
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- January 31, 2010
- Enrollment
- 478 (actual)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.